Mirum Pharmaceuticals reported a robust third quarter, achieving total net product revenue of $133 million, a 47% year-over-year increase, driven by strong sales of its flagship product, LIVMARLI. The U.S. market accounted for $64 million of LIVMARLI sales, while international contributions reached $28 million. The company also highlighted its first-ever GAAP profitability, posting a net income of $3 million and bolstering its cash position to $378 million, which supports ongoing investments in its expanding pipeline.

The results underscore Mirum’s solid commercial performance and the continued demand for its rare disease treatments, particularly in the U.S. and Japan. The updated revenue guidance for 2025, now projected between $500 million and $510 million, reflects ongoing strength in the bile acid portfolio and the anticipated impact of upcoming clinical data from studies like the VISTAS trial for volixibat, which is expected to yield results in mid-2026.

For market professionals, Mirum’s ability to achieve profitability while expanding its product portfolio positions it favorably for future growth, particularly as it seeks to capitalize on the peak revenue potential exceeding $1 billion for key products. This momentum, coupled with a strong cash position, makes Mirum a company to watch in the biopharmaceutical sector.

Source: fool.com